Edward J. Dulac III

2021

In 2021, Edward J. Dulac III earned a total compensation of $6.4M as Chief Financial Officer at Fate Therapeutics, a 12% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$168,000
Option Awards$500,000
Salary$420,000
Stock Awards$5,296,051
Total$6,384,051

Dulac received $5.3M in stock awards, accounting for 83% of the total pay in 2021.

Dulac also received $168K in non-equity incentive plan, $500K in option awards and $420K in salary.

Rankings

In 2021, Edward J. Dulac III's compensation ranked 1,993rd out of 12,415 executives tracked by ExecPay. In other words, Dulac earned more than 83.9% of executives.

ClassificationRankingPercentile
All
1,993
out of 12,415
84th
Division
Manufacturing
758
out of 5,505
86th
Major group
Chemicals And Allied Products
294
out of 2,375
88th
Industry group
Drugs
253
out of 2,096
88th
Industry
Biological Products, Except Diagnostic Substances
79
out of 449
82nd
Source: SEC filing on April 25, 2022.

Dulac's colleagues

We found five more compensation records of executives who worked with Edward J. Dulac III at Fate Therapeutics in 2021.

2021

J Wolchko

Fate Therapeutics

Chief Executive Officer

2021

Mark Plavsic

Fate Therapeutics

Chief Technology Officer

2021

Bahram Valamehr

Fate Therapeutics

Chief Research and Development Officer

2021

Cindy Tahl

Fate Therapeutics

General Counsel

2021

Yu-Waye Chu

Fate Therapeutics

Chief Medical Officer

News

You may also like